Global Cystic Fibrosis Transmembrane Conductance Regulator Cftr Market
市场规模(十亿美元)
CAGR : %
Forecast Period |
2023 –2030 |
Market Size (Base Year) |
USD 7.18 Billion |
Market Size (Forecast Year) |
USD 42.23 Billion |
CAGR |
|
Major Markets Players |
全球囊性纤维化跨膜传导调节器 (CFTR) 市场,按药物类别(CFTR 调节剂、粘液溶解剂、支气管扩张剂、胰酶补充剂)、应用(先天性双侧输精管缺失、囊性纤维化、遗传性胰腺炎等)、剂量(液体、喷雾剂、注射剂等)、给药途径(口服、吸入)、最终用户(医院、家庭护理、专科诊所等)、分销渠道(医院药房、网上药房、零售药房)划分 - 行业趋势和预测到 2030 年。
囊性纤维化跨膜传导调节器 (CFTR) 市场分析和规模
人们对这种渐进性遗传疾病的认识不断提高,药物疗法的采用率不断上升,这是推动囊性纤维化市场增长的一些主要因素。据观察,基于给药途径,口服药物正在推动囊性纤维化市场的发展。此外,首个囊性纤维化跨膜传导调节器 (CFTR) 调节剂的获批改变了精准医疗时代的囊性纤维化格局。
Data Bridge Market Research 分析了 2023-2030 年预测期内囊性纤维化跨膜传导调节器 (CFTR) 市场的增长率。在上述预测期内,囊性纤维化跨膜传导调节器 (CFTR) 市场的预期复合年增长率趋于 24.8% 左右。2022 年市场价值为 71.8 亿美元,到 2030 年将增长至 422.3 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外,Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
囊性纤维化跨膜传导调节器 (CFTR) 市场范围和细分
报告指标 |
细节 |
预测期 |
2023-2030 |
基准年 |
2022 |
历史岁月 |
2021(可定制为 2015 - 2020) |
定量单位 |
收入(单位:十亿美元)、销量(单位:台)、定价(美元) |
涵盖的领域 |
药物类别(CFTR 调节剂、粘液溶解剂、支气管扩张剂、胰酶补充剂)、用途(先天性双侧输精管缺失、囊性纤维化、遗传性胰腺炎、其他)、剂量(液体、喷雾剂、注射剂、其他)、给药途径(口服、吸入)、最终用户(医院、家庭护理、专科诊所、其他)、分销渠道(医院药房、网上药房、零售药房) |
覆盖国家 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
Market Players Covered |
Genentech Inc. (U.S.), Gilead Sciences, Inc. (U.S.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Johnson & Johnson Private Limited (U.S.), Abbvie, Inc (U.S.), Mylan N.V. (U.S.), Pharmaxis Ltd (Australia), Vertex Pharmaceuticals Incorporated (U.S.) |
Market Opportunities |
|
Market Definition
The cystic fibrosis transmembrane conductance regulator (CFTR) gene codes for an ABC transporter-class ion channel protein which conducts chloride and bicarbonate ions across epithelial cell membranes. The CFTR protein is made as per the instructions from the CFTR gene. This protein acts as a channel between cells, generating sweat, saliva, mucus, tears, and digestive enzymes. Chloride ions are negatively charged and are transported into and out of cells through this channel.
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Dynamics
Drivers
- Increased Cases of Cystic Fibrosis
As per the records of Cystic Fibrosis Patient Registry, more than 30,000 people are at present suffering from this condition in the U.S., while more than 70,000 people are claimed to be suffering from it globally. Additionally, around 1000 new cases of the disease are diagnosed each year. The rising occurrence of this disease is likely to increase the demand for combination treatments that will boost the industry progression in the coming years.
- Increasing Demand of Oral Segment
The oral segment is dominating the market for cystic fibrosis. The increased efficiency of orally administered medication in improving the quality of life and decreasing the intensity of symptoms is providing boost to the market growth of cystic fibrosis. In addition to this, the wide accessibility of oral medications such as Kalydeco, Ataluren, and N-acetylcysteine is also extending the development of the market. Furthermore, the increasing drift of patients towards oral treatments over intravenous therapy is resulting in the huge market growth. This boost the market growth.
Opportunities
- Growing R&D Activities on Cystic Fibrosis
Growing spending on R&D research in the industry and other technological advancements in this diseased condition will open new scopes of growth for industry participants. Growing funding for R&D projects on cystic fibrosis drugs and other government initiatives will boost the market growth. For instance, North American Cystic Fibrosis Conference (NACFC) has started providing educational forums to the cystic fibrosis community, allowing them to share the latest developments in the R&D space. Furthermore, the U.S. FDA approved a new triple combination therapy, i.e., Trikafta, in October 2019 for treating cystic fibrosis patients. This novel therapy will increase the survival possibilities of these patients. In August 2021, Cystic Fibrosis Canada insisted on standardized adoption recommendations for patient access to Trikafta to improve patients' quality of life and increase the adoption rate of several treatment procedures.
Restraints/Challenges
- Discontinuation of Drug Trials
The drug development associated with the disease has faced many obstacles such as many therapies that have failed to reveal efficacy or were related with major toxicity. Thus, this hampers the growth of the market.
This cystic fibrosis transmembrane conductance regulator (CFTR) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cystic fibrosis transmembrane conductance regulator (CFTR) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2020, Roche and Abbvie announced the partnership and also acquired the TMEM 16A product portfolio. It is used in cystic fibrosis with a rare CFTR genotype and associated respiratory illnesses. This acquisition helped to boost the prospects.
- In 2019, AbbVie and Cystic Fibrosis Foundation (CFF) formed a huge strategic alliance to develop CFTR molecule. This partnership is bound to surge the product developments in the market
Global Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Scope
The cystic fibrosis transmembrane conductance regulator (CFTR) market is segmented on the basis of drug class, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- CFTR Modulators
- Kalydeco
- Orkambi
- Mucolytics
- Acetylcysteine
- Bromhexine
- Ambroxol
- Bronchodilators
- Beta-2 agonists
- Anticholinergics
- Pancreatic Enzyme Supplements
- Creon
- Zenpep
Application
- Congenital Bilateral Absence of the Vas Deferens
- Cystic Fibrosis
- Hereditary Pancreatitis
- Others
Dosage
- Liquids
- Sprays
- Injectables
- Others
Route of Administration
- Oral
- Inhaled
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Regional Analysis/Insights
The cystic fibrosis transmembrane conductance regulator (CFTR) market is analyzed and market size insights and trends are provided by drug class, application, dosage, route of administration, end-users and distribution channel as referenced above.
The major countries covered in the cystic fibrosis transmembrane conductance regulator (CFTR) market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific will be expecting positive growth for cystic fibrosis transmembrane conductance regulator (CFTR) market throughout the forecasted period due to the several government initiatives in countries to expand lifestyle of people surviving with rare diseases. The wide adoption of advanced technologies, digital tools for quick diagnosis, and major improvements in virtual consultations result in market growth.
North America dominates the market due to the growing research and development activities. Furthermore, the increasing presence of major market players will further enhance this region's growth rate.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Market Share Analysis
囊性纤维化跨膜传导调节剂 (CFTR) 市场竞争格局提供了按竞争对手划分的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对囊性纤维化跨膜传导调节剂 (CFTR) 市场的关注有关。
囊性纤维化跨膜传导调节器 (CFTR) 市场的主要参与者包括:
- 麒麟控股有限公司 (日本)
- Vericel Corporation(美国)
- Mereo Biopharma Group PLC(英国)
- 诺华公司(瑞士)
- AM-Pharma BV(荷兰)
- Alexion Pharmaceuticals, Inc.(美国)
- 拜耳公司(德国)
- 辉瑞公司(美国)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.